Trastuzumab (Herceptin) is a recombinant monoclonal antibody which shows its anti tumor activity by binding to the extracellular region of HER2 in HER2-positive breast cancer (Pegram et al.; 2000; Cho et al., 2003; Hudis, 2007). The gene discussed is ERBB2; the disease is breast carcinoma.